Intravenous Immunoglobulin (IVIG) Market by Application (Hypogammaglobulinemia, ChronicInflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others) and Type (IgG, IgA, IgM, IgE, and IgD): Global Opportunity Analysis and Industry Forecast, 2027
The Intravenous Immunoglobulin (IVIG) market refers to the pharmaceutical products and therapies involving the use of intravenous immunoglobulin for the treatment of various medical conditions. IVIG is a blood-derived product that contains antibodies, primarily immunoglobulin G (IgG), which is obtained from pooled plasma donations. Intravenous Immunoglobulin (IVIG) Market is likely to grow at a rate of 8.5% CAGR by 2027. The key factor which is majorly accelerating the growth of the Intravenous Immunoglobulin (IVIG) market is increasing prevalence of immunodeficiency disorders: The rising incidence of immunodeficiency disorders, such as primary immunodeficiency diseases (PIDD) and secondary immunodeficiency diseases (SID), is a significant driver for the IVIG market. IVIG therapy is commonly used to treat these disorders and enhance the immune system's functioning. On the contrary, the high risk of side effects associated with them Intravenous Immunoglobulin products may restrict the market5 growth.
The Intravenous Immunoglobulin (IVIG) Market by Application
Hypogammaglobulinemia
Chronic Inflammatory demyelinating polyneuropathy (CIDP)
Primary immunodeficiency diseases
Myasthenia Gravis
Multifocal motor neuropathy
Idiopathic thrombocytopenic purpura (ITP)
Inflammatory myopathies
Specific antibody deficiency
Guillain-Barre syndrome
The Intravenous Immunoglobulin (IVIG) Market by Product
IGG
IGA
IGM
IGE
IGD
The Intravenous Immunoglobulin (IVIG) Market by Geography
North America
Europe
Asia Pacific
Rest of the World
IVIG is used for the treatment of several conditions, including:
Primary Immunodeficiency Disorders: Intravenous Immunoglobulin is commonly used in individuals with primary immunodeficiency disorders, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA). These conditions result in a deficiency of antibodies, and IVIG helps boost the immune response and provide protection against infections.
Neurological Disorders: Intravenous Immunoglobulin has shown efficacy in the treatment of certain neurological disorders, such as Guillain-BarrŠ¹ syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). The precise mechanisms by which IVIG exerts its effects in these conditions are not fully understood but are believed to involve modulating the immune response and reducing inflammation.
Autoimmune Disorders: Intravenous Immunoglobulin (IVIG) is also used in the management of various autoimmune disorders, including systemic lupus erythematosus (SLE), dermatomyositis, and Kawasaki disease. It is thought to exert its therapeutic effects by modulating the immune system and suppressing autoimmune reactions.
Hematological Disorders: Intravenous Immunoglobulin is sometimes utilized in the treatment of certain hematological disorders, such as immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). It helps increase platelet counts and reduce the destruction of red blood cells, respectively.
The IVIG market is driven by the increasing prevalence of immunodeficiency disorders, autoimmune diseases, and neurological conditions. Pharmaceutical companies collect plasma donations from healthy individuals, process the plasma to obtain immunoglobulins, and produce Intravenous Immunoglobulin products for clinical use.
IVIG is administered intravenously under medical supervision, typically in hospital settings or specialized infusion centers. The market includes healthcare providers, hospitals, clinics, and infusion centers that administer IVIG treatments. It also encompasses diagnostic laboratories involved in screening plasma donations for infectious diseases and ensuring the safety and quality of Intravenous Immunoglobulin products.
The major leading companies of the Intravenous Immunoglobulin (IVIG) market are Baxter International Inc., Bayer Ag, Biotest Ag, China Biologic Products, Inc., Csl Limited, Grifols S.A., Kedrion Biopharma Inc., Lfb Sa (Lfb Biotechnologies Sas), Octapharma Ag, Takeda Pharmaceutical Company Limited.
The IVIG market is competitive, with multiple pharmaceutical companies involved in the production and distribution of Intravenous Immunoglobulin products. Research and development efforts focus on improving manufacturing processes, ensuring product safety, and exploring new therapeutic indications for IVIG.
It's worth noting that the availability and accessibility of IVIG may vary across different regions due to regulatory requirements, plasma supply, and healthcare infrastructure.
It's worth noting that market trends and dynamics can change over time. For the most up-to-date information on the current state of the cephalosporin market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the Intravenous Immunoglobulin (IVIG) market in the forecast period.
An exact estimation of the Intravenous Immunoglobulin (IVIG) market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
The Intravenous Immunoglobulin (IVIG) Market by Application
Hypogammaglobulinemia
Chronic Inflammatory demyelinating polyneuropathy (CIDP)
Primary immunodeficiency diseases
Myasthenia Gravis
Multifocal motor neuropathy
Idiopathic thrombocytopenic purpura (ITP)
Inflammatory myopathies
Specific antibody deficiency
Guillain-Barre syndrome
The Intravenous Immunoglobulin (IVIG) Market by Product
IGG
IGA
IGM
IGE
IGD
The Intravenous Immunoglobulin (IVIG) Market by Geography
North America
Europe
Asia Pacific
Rest of the World
IVIG is used for the treatment of several conditions, including:
Primary Immunodeficiency Disorders: Intravenous Immunoglobulin is commonly used in individuals with primary immunodeficiency disorders, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA). These conditions result in a deficiency of antibodies, and IVIG helps boost the immune response and provide protection against infections.
Neurological Disorders: Intravenous Immunoglobulin has shown efficacy in the treatment of certain neurological disorders, such as Guillain-BarrŠ¹ syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). The precise mechanisms by which IVIG exerts its effects in these conditions are not fully understood but are believed to involve modulating the immune response and reducing inflammation.
Autoimmune Disorders: Intravenous Immunoglobulin (IVIG) is also used in the management of various autoimmune disorders, including systemic lupus erythematosus (SLE), dermatomyositis, and Kawasaki disease. It is thought to exert its therapeutic effects by modulating the immune system and suppressing autoimmune reactions.
Hematological Disorders: Intravenous Immunoglobulin is sometimes utilized in the treatment of certain hematological disorders, such as immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). It helps increase platelet counts and reduce the destruction of red blood cells, respectively.
The IVIG market is driven by the increasing prevalence of immunodeficiency disorders, autoimmune diseases, and neurological conditions. Pharmaceutical companies collect plasma donations from healthy individuals, process the plasma to obtain immunoglobulins, and produce Intravenous Immunoglobulin products for clinical use.
IVIG is administered intravenously under medical supervision, typically in hospital settings or specialized infusion centers. The market includes healthcare providers, hospitals, clinics, and infusion centers that administer IVIG treatments. It also encompasses diagnostic laboratories involved in screening plasma donations for infectious diseases and ensuring the safety and quality of Intravenous Immunoglobulin products.
The major leading companies of the Intravenous Immunoglobulin (IVIG) market are Baxter International Inc., Bayer Ag, Biotest Ag, China Biologic Products, Inc., Csl Limited, Grifols S.A., Kedrion Biopharma Inc., Lfb Sa (Lfb Biotechnologies Sas), Octapharma Ag, Takeda Pharmaceutical Company Limited.
The IVIG market is competitive, with multiple pharmaceutical companies involved in the production and distribution of Intravenous Immunoglobulin products. Research and development efforts focus on improving manufacturing processes, ensuring product safety, and exploring new therapeutic indications for IVIG.
It's worth noting that the availability and accessibility of IVIG may vary across different regions due to regulatory requirements, plasma supply, and healthcare infrastructure.
It's worth noting that market trends and dynamics can change over time. For the most up-to-date information on the current state of the cephalosporin market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the Intravenous Immunoglobulin (IVIG) market in the forecast period.
An exact estimation of the Intravenous Immunoglobulin (IVIG) market share and its contribution to the parent market is provided in the report.
Further profiles of leading competitors and their dynamic strategies are also covered in thestudy.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. APPLICATION: MARKET SIZE & ANALYSIS
5.1. Hypogammaglobulinemia
5.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
5.3. Primary immunodeficiency diseases
5.4. Myasthenia Gravis
5.5. Multifocal motor neuropathy
5.6. Idiopathic thrombocytopenic purpura (ITP)
5.7. Inflammatory myopathies
5.8. Specific antibody deficiency
5.9. Guillain-Barre syndrome
6. PRODUCT: MARKET SIZE & ANALYSIS
6.1. IGG
6.2. IGA
6.3. IGM
6.4. IGE
6.5. IGD
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. BAXTER INTERNATIONAL INC.
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. BAYER AG.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. BIOTEST AG
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. CHINA BIOLOGIC PRODUCTS, INC
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. CSL LIMITED
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. GRIFOLS S.A
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. KEDRION BIOPHARMA INC
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. LFB SA
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Transenterix, Inc
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. OCTAPHARMA AG.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
9.11. OCTAPHARMA AG.
9.11.1. Overview
9.11.2. Financial Overview
9.11.3. Product Offerings
9.11.4. Developments
9.11.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. APPLICATION: MARKET SIZE & ANALYSIS
5.1. Hypogammaglobulinemia
5.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
5.3. Primary immunodeficiency diseases
5.4. Myasthenia Gravis
5.5. Multifocal motor neuropathy
5.6. Idiopathic thrombocytopenic purpura (ITP)
5.7. Inflammatory myopathies
5.8. Specific antibody deficiency
5.9. Guillain-Barre syndrome
6. PRODUCT: MARKET SIZE & ANALYSIS
6.1. IGG
6.2. IGA
6.3. IGM
6.4. IGE
6.5. IGD
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia Pacific
7.5. Rest of the World
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. BAXTER INTERNATIONAL INC.
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. BAYER AG.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. BIOTEST AG
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. CHINA BIOLOGIC PRODUCTS, INC
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. CSL LIMITED
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. GRIFOLS S.A
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. KEDRION BIOPHARMA INC
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. LFB SA
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Transenterix, Inc
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. OCTAPHARMA AG.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
9.11. OCTAPHARMA AG.
9.11.1. Overview
9.11.2. Financial Overview
9.11.3. Product Offerings
9.11.4. Developments
9.11.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR HYPOGAMMAGLOBULINEMIA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR PRIMARY IMMUNODEFICIENCY DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR MYASTHENIA GRAVIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR MULTIFOCAL MOTOR NEUROPATHY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR INFLAMMATORY MYOPATHIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR SPECIFIC ANTIBODY DEFICIENCY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR GUILLAIN-BARRE SYNDROME, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGG, 2021-2027 (USD BILLION
TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGM, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGD, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 18. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 19. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 20. U.SINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 21. U.SINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 22. CANADAINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 23. CANADAINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 24. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 27. GERMANY ACTINIC KERATOSI TREATMENT MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 29. U.K INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. U.K INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 31. FRANCE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 32. FRANCE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 33. ITALY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 34. ITALY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 35. SPAIN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. SPAIN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 37. ROE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 38. ROE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 39. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 40. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 41. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 42. CHINA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 43. CHINA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 44. INDIA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 45. INDIA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 46. JAPAN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 47. JAPAN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 48. REST OF APAC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 49. REST OF APAC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 50. REST OF WORLD INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COMPONENT, 2021-2027 (USD BILLION)
TABLE 51. REST OF WORLD INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 52. BAXTER INTERNATIONAL INC: FINANCIALS
TABLE 53. BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES
TABLE 54. BAXTER INTERNATIONAL INC: RECENT DEVELOPMENTS
TABLE 55. BAYER AG: FINANCIALS
TABLE 56. BAYER AG: PRODUCTS & SERVICES
TABLE 57. BAYER AG: RECENT DEVELOPMENTS
TABLE 58. BIOTEST AG: FINANCIALS
TABLE 59. BIOTEST AG: PRODUCTS & SERVICES
TABLE 60. BIOTEST AG: RECENT DEVELOPMENTS
TABLE 61. CHINA BIOLOGIC PRODUCTS, INC: FINANCIALS
TABLE 62. CHINA BIOLOGIC PRODUCTS, INC: PRODUCTS & SERVICES
TABLE 63. CHINA BIOLOGIC PRODUCTS, INC: RECENT DEVELOPMENTS
TABLE 64. CSL LIMITED: FINANCIALS
TABLE 65. CSL LIMITED: PRODUCTS & SERVICES
TABLE 66. CSL LIMITED: RECENT DEVELOPMENTS
TABLE 67. GRIFOLS S.A: FINANCIALS
TABLE 68. GRIFOLS S.A: PRODUCTS & SERVICES
TABLE 69. GRIFOLS S.A: RECENT DEVELOPMENTS
TABLE 70. KEDRION BIOPHARMA INC: FINANCIALS
TABLE 71. KEDRION BIOPHARMA INC: PRODUCTS & SERVICES
TABLE 72. KEDRION BIOPHARMA INC: RECENT DEVELOPMENTS
TABLE 73. LFB SA: FINANCIALS
TABLE 74. LFB SA: PRODUCTS & SERVICES
TABLE 75. LFB SA: RECENT DEVELOPMENTS
TABLE 76. OCTAPHARMA AG: FINANCIALS
TABLE 77. OCTAPHARMA AG: PRODUCTS & SERVICES
TABLE 78. OCTAPHARMA AG: RECENT DEVELOPMENTS
TABLE 79. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 80. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 81. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR HYPOGAMMAGLOBULINEMIA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR PRIMARY IMMUNODEFICIENCY DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR MYASTHENIA GRAVIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR MULTIFOCAL MOTOR NEUROPATHY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR INFLAMMATORY MYOPATHIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR SPECIFIC ANTIBODY DEFICIENCY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR GUILLAIN-BARRE SYNDROME, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGG, 2021-2027 (USD BILLION
TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGM, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE FOR IGD, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 18. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 19. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 20. U.SINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 21. U.SINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 22. CANADAINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 23. CANADAINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 24. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPEINTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 27. GERMANY ACTINIC KERATOSI TREATMENT MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 29. U.K INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. U.K INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 31. FRANCE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 32. FRANCE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 33. ITALY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 34. ITALY INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 35. SPAIN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. SPAIN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 37. ROE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 38. ROE INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 39. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 40. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 41. ASIA PACIFC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 42. CHINA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 43. CHINA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 44. INDIA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 45. INDIA INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 46. JAPAN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 47. JAPAN INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 48. REST OF APAC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 49. REST OF APAC INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 50. REST OF WORLD INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY COMPONENT, 2021-2027 (USD BILLION)
TABLE 51. REST OF WORLD INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET VALUE, BY PRODUCT, 2021-2027 (USD BILLION)
TABLE 52. BAXTER INTERNATIONAL INC: FINANCIALS
TABLE 53. BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES
TABLE 54. BAXTER INTERNATIONAL INC: RECENT DEVELOPMENTS
TABLE 55. BAYER AG: FINANCIALS
TABLE 56. BAYER AG: PRODUCTS & SERVICES
TABLE 57. BAYER AG: RECENT DEVELOPMENTS
TABLE 58. BIOTEST AG: FINANCIALS
TABLE 59. BIOTEST AG: PRODUCTS & SERVICES
TABLE 60. BIOTEST AG: RECENT DEVELOPMENTS
TABLE 61. CHINA BIOLOGIC PRODUCTS, INC: FINANCIALS
TABLE 62. CHINA BIOLOGIC PRODUCTS, INC: PRODUCTS & SERVICES
TABLE 63. CHINA BIOLOGIC PRODUCTS, INC: RECENT DEVELOPMENTS
TABLE 64. CSL LIMITED: FINANCIALS
TABLE 65. CSL LIMITED: PRODUCTS & SERVICES
TABLE 66. CSL LIMITED: RECENT DEVELOPMENTS
TABLE 67. GRIFOLS S.A: FINANCIALS
TABLE 68. GRIFOLS S.A: PRODUCTS & SERVICES
TABLE 69. GRIFOLS S.A: RECENT DEVELOPMENTS
TABLE 70. KEDRION BIOPHARMA INC: FINANCIALS
TABLE 71. KEDRION BIOPHARMA INC: PRODUCTS & SERVICES
TABLE 72. KEDRION BIOPHARMA INC: RECENT DEVELOPMENTS
TABLE 73. LFB SA: FINANCIALS
TABLE 74. LFB SA: PRODUCTS & SERVICES
TABLE 75. LFB SA: RECENT DEVELOPMENTS
TABLE 76. OCTAPHARMA AG: FINANCIALS
TABLE 77. OCTAPHARMA AG: PRODUCTS & SERVICES
TABLE 78. OCTAPHARMA AG: RECENT DEVELOPMENTS
TABLE 79. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 80. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 81. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
